American Express Raises Dividend 17% As Profits Hit Record Levels
Credit card giant American Express (AXP) has raised its quarterly dividend payment by 17% after reporting record revenue and net income for 2024. The New York City-based company reported fourth quarter 2024 earnings per share (EPS) of $3.04 U.S., which narrowly beat Wall Street’s forecast of $3.03 U.S. Revenue in the quarter totaled $17.18 billon U.S., which also was slightly above the consensus estimate of $17.16 billion U.S. Spending by credit card holders rose 8% from a year ago. For all of 2024, American Express delivered record revenue of $65.90 billion U.S., as well as record net income of $10.10 billion U.S. Earnings per share in 2024 totaled $14.01 U.S., up 25% from the previous year. American Express also said that it achieved record levels of annual card member spending, record net card fee revenues, and a record 13 million new card acquisitions during the year. Owing to the record results, American Express increased its quarterly dividend payout by 17% to $0.82 U.S. per share. Looking ahead, the company said that it expects revenue growth of between 8% and 10%, and earnings per share of $15 U.S. to $15.50 U.S. for all of 2025. Analysts who track the company’s progress had forecast 2025 earnings of $15.24 U.S. a share. The stock of American Express has increased 75% over the last 12 months to trade at $325.87 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


